Pharmacodynamic approaches to the use of mucoactive drugs
https://doi.org/10.26295/OS.2020.62.62.001
Abstract
Cough is a reflex, protective and adaptive reaction of the body aimed at removing foreign sub-stances and/or pathologically altered tracheobronchial secretions from the respiratory tract. Cough is one of the most important components of pulmonary clearance, which is activated when natural mechanisms fail. It can have both a positive value (clearing the airways) and a negative value (it tires the patient, disrupts sleep, nutrition, and can lead to various complica-tions). Therefore, the treatment of cough using pharmacological and nonmedicinal methods can reduce it in the case of excessive severity and improve pulmonary clearance. The basis of cough pharmacotherapy is mucoactive drugs, which form four pharmacological groups: expectorants, mucolytics, mucokinetics, mucoregulators. In addition, in some cases, drugs can be used to suppress the cough reflex in the central or peripheral link. All of them provide symptomatic cough relief and reduce the duration of symptoms. The choice of medicines for the treatment of cough is determined by their pharmacodynamics and features of influence on the nature of bronchial secretions.
About the Authors
S. V. Okovity
Saint-Petersburg Chemical Pharmaceutical University
Russian Federation
Russian Federation
Saint Petersburg
A. A. Zaitsev
N. N. Burdenko Military Clinical Hospital
Russian Federation
Russian Federation
Moscow
N. A. Anisimova
Saint-Petersburg Chemical Pharmaceutical University
Russian Federation
Russian Federation
Saint Petersburg
References
1. Finley C. R., Chan D. S., Garrison S. et al. What are the most common conditions in primary care? Systematic review // Can Fam Physician. 2018; 64 (11): 832-840.
2. Morice A. H., McGarvey L., Pavord I. British Thoracic Society Cough Guideline Group. Recommendations for the management of cough in adults // Thorax. 2006; 61 (Suppl. 1): i1-i24.
3. Chuchalin A. G., Abrosimov V. N. Kashel [Cough]. M.: Echo, 2012 (in Russ.).
4. Poole P., Chong J., Cates C. J. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease // Cochrane Database Syst Rev. 2015; 7: CD001287.
5. Smith S. M., Schroeder K., Fahey T. Over-the-counter (OTC) medications for acute cough in children and adults in community settings // Cochrane Database Syst Rev. 2014; 11: CD001831.
6. Scaglione F., Petrini O. Mucoactive agents in the therapy of upper respiratory airways iInfections: fair to describe them just as mucoactive? // Clin Med Insights Ear Nose Throat. 2019; 12: 1179550618821930.
7. Kharkevich D. A. Farmakologiya [Pharmacology]. М.: GEOTARMedia, 2017 (in Russ.).
8. Amelina E. L., Anaev E. X., Krasovskyi S. A. et al. Mukoaktivnaya terapiya [Mucoactive therapy]. M.: Atmosphere, 2008 (in Russ.).
9. Okovityi S. V., Anisimova N. A. Farmakologicheskie podkhody k protivokashlevoi terapii [Pharmacological approaches to antitussive therapy] // RMJ. 2011; 23: 1450-457 (in Russ.).
10. Zaitsev A. A., Okovityi S. V. Kashel: differentsialnyi diagnoz I ratsionalnaya farmakoterapiya [Cough: Differential diagnosis and rational pharmacotherapy]. Terapevticheskii arkhiv. 2014; 12: 85-91 (in Russ.).
11. Albrecht H. H., Dicpinigaitis P. V., Guenin E. P. Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections // Multidiscip Respir Med. 2017; 12: 31.
12. Balsamo R., Lanata L., Egan C. G. Mucoactive drugs // Eur Respir Rev. 2010; 19 (116): 127-133.
13. Rubin B. K. The pharmacologic approach to airway clearance: mucoactive agents // Paediatr Respir Rev. 2006; 7 (Suppl 1): S215-219.
14. Sinopalnikov A. I., Klyachkina I. L. Kashel [Cough]. M.: MIA, 2013 (in Russ.).
15. Zaitsev A. A. Mukoaktivnaya farmakoterapiya: osnovy ratsionalnogo vybora [Mucoactive pharma-cotherapy: the basics of rational choice] // Prakticheskaya pulmonologiya. 2019; 3: 77-82 (In Russ.).
16. Rogers D. F. Mucoactive agents for airway mucus hypersecretory diseases // Respiratory Care. 2007; 52 (9): 1176-1197.
17. Dal Negro R. W., Visconti M., Turco P. Efficacy of erdosteine 900 versus 600 mg/day in reducing oxi-dative stress in patients with COPD exacerbations: results of a double blind, placebocontrolled trial // Pulm Pharmacol Ther. 2015; 33: 47-51.
18. Shen Y., Cai W., Lei S., Zhang Z. Effect of high/low dose N-acetylcysteine on chronic obstructive pulmonary disease: a systematic review and meta-analysis // COPD. 2014; 11 (3): 351-358.
19. Melnikova I. M., Mizernitsky Yu. I. Kombinirovannye otkharkivayuschie preparaty rastitelnogo proiskhozhdeniya v pediatricheskoi praktike [Combination herbal expectorants in pediatric practice] // Meditsinskii sovet. 2018; 2: 93-97 (In Russ.).
20. British National Formulary (BNF 67) / BMJ Group and the Royal Pharmaceutical Society of Great Britain. Pharmaceutical Press, 2014.
21. Kellett F., Robert N. M. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis // Respir Med. 2011; 105 (12): 1831-1835.
22. Gosudarsvennyi reestr lekarsvennykh lekarstvennykh sredstv [The State Register of Medicinal Products]: [Electronic resource]. Moscow, 2020. URL: http://grls.rosminzdrav.ru. (Accessed: 18.02.2020-.03.20).
23. Faruqi S., Wright C., Thompson R., Morice A. H. A randomized placebo controlled trial to evaluate the effects of butamirate and dextromethorphan on capsaicin induced cough in healthy volunteers // Br J Clin Pharmacol. 2014; 78 (6): 1272-1280.
24. Khronicheskaya obstruktivnaya bolezn legkikh: Klinicheskie rekomendatsii Possiiskogo respiratornogo obschestva [Chronic obstructive pulmonary disease: Clinical recommendations of the Russian respiratory society], 2018: [Electronic resource]. Moscow, MOO «Russian respiratory society», 2020. URL: http://grls.rosminzdrav.ru. (Accessed: 06.03.2020) (In Russ.).
25. Global Initiative for Chronic Obstructive Lung Disease, 2020: [Electronic resource]. GOLD, 2020. URL: https://goldcopd.org/ wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf. (Accessed: 06.03.2020).
26. Dal Negro R. W., Wedzicha J. A., Iversen M., Fontana G., Page C., Cicero A. F., Pozzi E., Calverley P.M.A.; RESTORE group Effect of erdosteine on the rate and duration of COPD exacerbations: the RE-STORE study // Eur Respir J. 2017; 50 (4): pii:1700711.
27. Moretti M., Bottrighi P., Dallari R., Da Porto R., Dolcetti A., Grandi P., Garuti G., Guffanti E., Roversi P., De Gugliemo M., Potena A. EQUALIFE Study Group. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE study // Drugs Exp Clin Res. 2004; 30 (4): 143-152.
28. Klyachkina I. L., Sinopalnikov A. I. Ambroksol v programme lecheniya khronicheskikh bronkhole-gochnykh zabolevanii [Ambroxol for the treatment of chronic bronchopulmonary diseases] // Prakticheskaya pulmonologiya. 2018; 2: 83-92 (In Russ.).
Review
For citations:
Okovity S.V., Zaitsev A.A., Anisimova N.A. Pharmacodynamic approaches to the use of mucoactive drugs. Lechaschi Vrach. 2020;(10):6-10. (In Russ.) https://doi.org/10.26295/OS.2020.62.62.001
Views:
375
JATS XML
Email this article 
